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Abstract
Background: Understanding how to sequence targeted therapies for metastatic renal
cell carcinoma (mRCC) is important for maximisation of clinical benefit.
Objectives: To prospectively evaluate sequential use of the multikinase inhibitors
sorafenib followed by sunitinib (So-Su) versus sunitinib followed by sorafenib (Su-So)
in patients with mRCC.
Design, setting, and participants: The [19_TD$DIFF]multicentre, randomised, open-label, phase 3
SWITCH study assessed So-Su versus Su-So in patients with mRCC without prior
systemic therapy, and stratiﬁed by Memorial Sloan Kettering Cancer Center risk score
(favourable or intermediate).
Intervention: Patients were randomised to sorafenib 400 mg twice daily followed, on
progression or intolerable toxicity, by sunitinib 50 mg once daily (4 wk on, 2 wk off)
(So-Su), or vice versa (Su-So).
Outcome measurements and statistical analysis: The primary endpoint was improve-
ment in progression-free survival (PFS) with So-Su versus Su-So, assessed from random-
isation to progression or death during second-line therapy. Secondary endpoints
included overall survival (OS) and safety.
* Corresponding author: Klinik fu¨r Urologie, Universita¨t Regensburg, am Caritas-Krankenhaus
St. Josef, Landshuter Straße 65, 93053 Regensburg, Germany. Tel. +49 941 7823504;
Fax: +49 941 7823515.
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0302-2838/# 2015 European Association of Urology. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Treatment of metastatic renal cell carcinoma (mRCC) has
greatly improved over the past decade with the introduction
of targeted therapies acting on vascular endothelial growth
factor receptor (VEGFR) or mammalian target of rapamycin
(mTOR) [1]. However, as most patients experience disease
progression during treatment with targeted therapy, sequen-
tial treatment with different agents has become standard
practice [2,3]. Choosing the sequence of agents to optimise
outcomes remains a key clinical challenge [3,4]. Sorafenib and
sunitinib are multikinase inhibitors with overlapping but not
identical kinase inhibition profiles. They target VEGFR 1–3,
platelet-derived growth factor receptor, and c-Kit [5,6];
sorafenib also targets BRAF and RET [6]. Both are approved
for the treatment of mRCC in first-line (sunitinib) and
cytokine-unsuitable (sorafenib) settings; sorafenib has
shown efficacy in multiple treatment lines [2,7–11].
In retrospective studies, sequential use of sorafenib and
sunitinib in mRCC was well tolerated and provided
additional clinical benefit beyond the use of either agent
alone; these retrospective studies suggested that outcomes
could be better with sorafenib followed by sunitinib (So-Su)
compared with sunitinib followed by sorafenib (Su-So)
[3,12–16]. The largest retrospective analysis at the time
[20_TD$DIFF]when the present study was designed (n = 189) revealed [21_TD$DIFF] a
numerically longer progression-free survival (PFS) for So-Su
than for Su-So (17.2 vs 11.7 mo) [15,17]. SWITCH was the
first prospective, randomised, phase 3 study to test the
hypothesis that sequential therapy with So-Su is superior
to Su-So in prolonging total PFS (defined as time from
randomisation to confirmed progression or death during
second-line therapy) in advanced/metastatic RCC.
2. Patients and methods
2.1. Study design and patients
SWITCH was a prospective, open-label, multicenter, randomised (1:1)
phase 3 study (NCT00732914). Eligibility criteria included age 18–85 yr;
advanced/metastatic RCC (all histologies); unsuitable for cytokine
therapy (established by the investigator according to patient character-
istics); no prior systemic therapy; Eastern Cooperative Oncology Group
performance status (ECOG PS) 0 or 1; one or more measurable lesions by
computed tomography (CT) or magnetic resonance imaging (MRI)
according to Response Evaluation Criteria in Solid Tumours (RECIST 1.0);
favourable or intermediate Memorial Sloan Kettering Cancer Center
(MSKCC) risk score [18]; and adequate bone marrow, liver, and renal
function. Exclusion criteria included unstable or severe cardiac disease;
active, clinically serious infections; and symptomatic metastatic brain
tumours. All patients gave written informed consent. The study complied
with local legal and regulatory requirements and the Declaration of
Helsinki/Good Clinical Practice guidelines.
Patients were randomised to sorafenib 400 mg twice daily followed
by sunitinib 50 mg once daily (4 wk on, 2 wk off) (So-Su) or vice versa
(Su-So). The treatment cycle length was 6 wk for both sorafenib and
sunitinib. Dose modiﬁcations to manage adverse events (AEs) were
permitted at the discretion of the investigator; the protocol included
recommendations on when and how to implement dose reductions,
interruptions, and permanent discontinuations. The sorafenib dose
could be reduced to 400 mg once daily and then 400 mg every other day.
The sunitinib dose could be reduced to 37.5 mg once daily and then
25 mg once daily. Randomisation was stratiﬁed by MSKCC score
(favourable vs intermediate). Centralised randomisation via fax was
coordinated by iOMEDICO AG (Germany). The randomisation list was
generated by ICRC Weyer GmbH using an SAS program. The person who
generated the randomisation list was not involved in the study project
management, monitoring, or data management.
First-line treatment in both arms continued until disease progression
according to RECIST or intolerable toxicity (after unsuccessful dose
reduction/interruption). There was a treatment-free crossover period of
1–4 wk after ﬁrst-line treatment to avoid additive toxicity. Patients who
discontinued ﬁrst-line treatment because of toxicity began second-line
treatment only after nonhaematological toxicity had resolved to grade
1 and haematological toxicity to grade 2. Patients who refused
further ﬁrst-line treatment because of toxicity could begin second-line
treatment if they consented and were in general compliance with the
study protocol.
2.2. Study endpoints and assessments
Supplementary Table 1 summarises the key endpoints. The primary
endpoint was total PFS (time from randomisation to conﬁrmed
progression or death during second-line therapy). First-line events
Results and limitations: In total, 365 patients were randomised (So-Su, n = 182; Su-So,
n = 183). There was no signiﬁcant difference in total PFS between So-Su and Su-So
(median 12.5 vs 14.9 mo; hazard ratio [HR] 1.01; 90% conﬁdence interval [CI] 0.81–1.27;
p = 0.5 for superiority). OSwas similar for So-Su and Su-So (median 31.5 and 30.2mo; HR
1.00, 90% CI 0.77–1.30; p = 0.5 for superiority). More So-Su patients than Su-So patients
reached protocol-deﬁned second-line therapy (57% vs 42%). Overall, adverse event rates
were generally similar between the treatment arms. The most frequent any-grade
treatment-emergent ﬁrst-line adverse events were diarrhoea (54%) and hand-foot skin
reaction (39%) for sorafenib; and diarrhoea (40%) and fatigue (40%) for sunitinib.
Conclusions: Total PFS was not superior with So-Su versus Su-So. These results demon-
strate that sorafenib followed by sunitinib and vice versa provide similar clinical beneﬁt
in mRCC.
Patient summary: We investigated if total progression-free survival (PFS) is improved in
patientswith advanced/metastatic kidney cancerwho are treatedwith sorafenib and then
with sunitinib (So-Su), comparedwith sunitinib and then sorafenib (Su-So).We found that
total PFS was not improved with So-Su compared with Su-So, but both treatment options
were similarly effective in patients with advanced/metastatic kidney cancer.
Trial registration: ClinicalTrials.gov identiﬁer NCT00732914, www.clinicaltrials.gov
# 2015 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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were used for patients who did not switch to per-protocol second-line
therapy. Patients without tumour progression or death were censored at
their last date for tumour evaluation. Secondary endpoints included
overall survival (OS; time from randomisation to time of death from
any cause); ﬁrst-line PFS (time from randomisation to conﬁrmed
progression or death during ﬁrst-line therapy); second-line PFS (time
from ﬁrst day of second-line therapy to conﬁrmed progression or death
during second-line therapy); objective response rate (ORR; complete or
partial responses) and disease control rate (DCR; complete or partial
responses or stable disease for 8 wk) during ﬁrst-line and second-line
therapy; total time to progression (TTP; time from randomisation
to conﬁrmed progression during second-line therapy); and time to
ﬁrst-line treatment failure (time from randomisation to progression,
death, or discontinuation due to toxicity). The tumour response was
assessed according to RECIST by CT/MRI after every second cycle
(ie, every 12 wk). Responses were conﬁrmed by repeat CT/MRI at least
4 wk after being ﬁrst recorded. Crossover from ﬁrst-line to second-line
treatment required a CT scan, which was the baseline scan for second-
line treatment. Safety was assessed [22_TD$DIFF] for each treatment line using
National Cancer Institute Common Terminology Criteria for Adverse
Events v3.0 at 0, 3, 6, 9, and 12 wk, and then every 6 wk and at treatment
end. Cardiotoxicity was assessed by monitoring left ventricular ejection
fraction (LVEF) andN-terminal pro-brain natriuretic peptide (NT-proBNP)
levels. LVEF was determined by echocardiography at baseline, then
every 12 wk, on the last day of ﬁrst-line treatment, and treatment
end. NT-proBNP was measured at baseline, on day 1 of each cycle, on
the last day of ﬁrst-line treatment, and at treatment end.
2.3. Statistical analysis
SWITCHwas planned as a noninferiority study based on data available in
2008, with a planned sample size of 540 patients to observe 381 events.
However, with the emergence of considerable retrospective data
suggesting that So-Su might provide longer combined PFS and OS than
Su-So (particularly the large retrospective study by Porta et al [15]),
SWITCHwas amended in June 2010 to a superiority design; 138 patients
had already been randomised. The sample size for the superiority design
was originally based on the following assumptions: overall PFS of
17.2 versus 11.7mo for So-Su versus Su-So [17]; accrual period of 36mo;
total treatment duration of 54 mo; 231 events; and 10% of patients not
evaluable for statistical analysis. A sample size of 346would provide 90%
power to show a 47% increase in total PFS. A protocol amendment in
August 2013, after all planned patients had been randomised, reduced
the power from 90% to 85%, and thus reduced the required sample size to
272 patients to show 194 events. This amendment was made because
of a slower than expected rate of events.
Efﬁcacy was assessed in the intention-to-treat (ITT) population,
which included all randomised patients; for ORR and DCR, only patients
who received at least one dose of study drug in the respective treatment
line were included. Missing values were not imputed. For time-to-event
analysis, missing values were censored. Details of event handling with
respect to the primary endpoint are given in Supplementary Table 2. In
particular, patients were censored if they received unauthorised cancer
treatment (without progressive disease or other status counted as an
event), which included patients who received off-protocol second-line
therapy instead of per-protocol second-line therapy. It also included
patients who ultimately received the correct sequence but not per
protocol; for example, a patient who received second-line sorafenib
>4 wk after stopping ﬁrst-line sunitinib would be recorded as receiving
off-protocol second-line therapy. Time-to-event endpoints were
assessed using a one-sided log-rank test with a signiﬁcance level of
a = 0.05. The log-rank test is symmetric: the calculated p values are the
samewhether the test is one- or two-sided, although the signiﬁcance level
for the two-sided test would be halved to 0.025. For PFS, OS, TTP, and time
to ﬁrst-line treatment failure, hazard ratios (HRs) and two-sided 90%
conﬁdence intervals (CIs) were derived from a Cox proportional hazard
model. ORR and DCR were assessed using Fisher’s exact test. Post hoc
analysis assessed differences between treatment arms for total PFS, OS,
and ﬁrst-line PFS in subgroups for age (>65 vs 65 yr), sex, MSKCC score
(favourable vs intermediate), and ECOG PS (0 vs 1). A further post hoc
analysis evaluated updated OS, with a data cutoff of January 14, 2014,
using 172 events. No corrections were made for multiple hypothesis
testing. Safety was assessed in all patients receiving at least one dose of
study treatment and was summarised using descriptive statistics.
3. Results
3.1. Patients
From February 2009 to December 2011, 365 patients were
randomised (182 to So-Su; 183 to Su-So) at 72 centres in
Germany, Austria, and the Netherlands (Fig. 1). Patient
demographics and baseline characteristics were well
balanced between the treatment groups (Table 1). Although
the study protocol mandated that patients should not have
received prior treatment and should be unsuitable for
cytokines, seven patients had prior interferon-a and
[23_TD$DIFF]four patients had prior interleukin-2. These patients were
included in the analyses under the intention-to-treat
principle. At data cutoff for all analyses (August 15,
2013), the mean follow-up (from last treatment to end of
follow-up) was 10.3 mo. Overall, 353 (97%) patients
received first-line treatment and 179 (49%) patients
received second-line treatment. More patients reached
protocol-defined second-line therapy in the So-Su arm
(n = 103, 57%) than in the Su-So arm (n = 76, 42%; p < 0.01;
Fig. 1). When the 13 So-Su and 24 Su-So patients receiving
documented, non–protocol-defined second-line therapy
were included, the difference was no longer statistically
significant (n = 116 [64%] vs n = 100 [55%]; p = 0.09). Of the
103 So-Su patients and 76 Su-So patients who received per-
protocol first- and second-line therapy, 52 and 36 patients,
respectively, went on to receive further treatment. Subse-
quent therapy for patients who discontinued the study
after first-line therapy and for those who received both
first- and second-line therapy is detailed in Supplementary
Table 3, and typically includedmTOR inhibitors (everolimus
and temsirolimus) and VEGF(R) inhibitors (bevacizumab/
interferon, pazopanib, sunitinib, sorafenib). Some patients
received second-line sorafenib or sunitinib outside of the
study protocol, mostly because of a treatment break longer
than the protocol-specified 28 d.
In both groups, the most common reason for stopping
first-line therapywasdisease progression. Themost frequent
reasons for not initiating protocol-defined second-line
treatment after stopping first-line treatment were death
(So-Su n = 16 [8.8%]; Su-So n = 19 [10%]) and adverse events
(So-Su n = 8 [4.4%]; Su-So n = 17 [9.3%]; Fig. 1). Demographic
and baseline characteristics were generally similar between
patients who received first-line therapy only and those
who received both first- and second-line therapy, although
patients not progressing to second-line therapy typically
had a less favourable MSKCC score and ECOG PS and
more previous treatment; in addition, fewer patients had
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undergone nephrectomy and more had non–clear-cell
histology (Supplementary Table 4).
3.2. Efficacy
At data cutoff (August 15, 2013), the primary objective was
not met: So-Su was not superior to Su-So in terms of PFS
(median 12.5 vs 14.9 mo; HR 1.01, 90% CI 0.81–1.27;
p = 0.5 for superiority; Fig. 2A). OS was similar in both arms
(median 31.5 mo for So-Su and 30.2 mo for Su-So; HR 1.00,
90% CI 0.77–1.30; p = 0.5 for superiority; Fig. 2B). Median
follow-up for patients without an OS event was 1.4 mo for
So-Su and 3.0 mo for Su-So. Median first-line PFS was also
similar between the two groups (5.9 mo for So-Su vs 8.5 mo
for Su-So; HR 1.19, 90% CI 0.97–1.47; p = 0.9 for superiority;
Fig. 3a). Median second-line PFS was longer for So-Su than
for Su-So (5.4 vs 2.8 mo; HR 0.55, 90% CI 0.41–0.74;
p < 0.001 for superiority; Fig. 3B). ORR and DCR were
similar during first-line treatment with sorafenib and
sunitinib. During second-line treatment, ORR and DCR
were higher for sunitinib than for sorafenib (p = 0.03 for
DCR; Table 2). Median time to first-line treatment failure
(6.0 vs 9.0 mo; HR 1.15, 90% CI 0.93–1.42; p = 0.9 for
superiority) andmedian total TTP (15.2 vs 17.2mo; HR 1.01,
90% CI 0.79–1.30; p = 0.5 for superiority) were comparable
between the So-Su and Su-So groups.
Updated survival analysis (data cutoff January 14, 2014)
revealed median OS of 30.0 mo for So-Su and 27.4 mo for
Su-So (HR 0.99, 90% CI 0.77–1.27; p = 0.5 for superiority;
Supplementary Fig. 1) [19].
Efficacy findings in the per-protocol population were
generally consistent with those in the ITT population (data
not shown), except for the interim OS analysis (31.5 mo for
So-Su vs 35.6 mo for Su-So; HR 1.06, 90% CI 0.80–1.42;
[(Fig._1)TD$FIG]
365 randomised
161 stopped 1st-line Soa
105 progressive disease
19 adverse events
7 withdrew consent
4 died
3 health deterioration
16 unknown
7 other reasonsb
156 stopped 1st-line Sua
91 progressive disease
29 adverse events
6 withdrew consent
3 died
5 health deterioration
13 unknown
9 other reasonsb
91 stopped 2nd-line Sua
67 progressive disease
7 adverse events
3 died
5 health deterioration
9 other reasonsb
71 stopped 2nd-line Soa
53 progressive disease
6 adverse events
4 withdrew
3 died
1 health deterioration
4 other reasonsb
182 (100%) assigned to So-Su
177 (97%) received 1st-line So
103 (57%) received 2nd-line Su*
12 (7%) still on 2nd-line Su
183 (100%) assigned to Su-So
176 (96%) received 1st-line Su
76 (42%) received 2nd-line So*
*p < 0.01
5 (3%) still on 2nd-line So
5 not treated
1 screening failure
2 consent withdrawn
2 other
7 not treated
2 investigator decision
2 consent withdrawn
3 other
58 (32%) not treated in 2nd-line
16 died
9 withdrew consent
8 adverse events
7 health deterioration
4 prolonged treatment interruption
8 unknown/missing
6 other reasonsb
80 (44%) not treated in 2nd-line
19 died
13 withdrew consent
17 adverse events
6 health deterioration
5 prolonged treatment interruption
10 unknown/missing
10 other reasonsb
16 (9%) still on 1st-line So 20 (11%) still on 1st-line Su
Fig. 1 – Patient disposition.
a Reasons for stopping treatment as reported by the investigator.
b Other reasons included investigator decision, lost to follow-up, and noncompliance.
So = sorafenib; Su = sunitinib.
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p = 0.6 for superiority). In the updated analysis, median OS
in the per-protocol population (31.5 mo for So-Su vs
30.2 mo for Su-So; HR 1.06, 90% CI 0.81–1.40; p = 0.6 for
superiority) was again consistent with that in the ITT
population.
3.3. Safety
The safety population included 177 So-Su patients and
176 Su-So patients who received at least one dose of first-
line study treatment. The safety results are summarised in
Table 3. The mean duration of first-line therapy was not
significantly different between sorafenib and sunitinib (log
rank test p = 0.1). During second-line treatment, the mean
duration of therapy was shorter for sorafenib (Su-So arm)
than for sunitinib (So-Su arm; log rank test p < 0.001). The
mean ( standard deviation) treatment break between first-
and second-line therapy (excluding the regular 2-wk interval
after sunitinib) was 21  16 d for So-Su and 17  14 d for
Su-So (p = 0.1). The most common treatment-emergent AEs
were diarrhoea, hand-foot skin reaction, hypertension, and
fatigue for first-line sorafenib, and diarrhoea, fatigue, hyper-
tension, and nausea for first-line sunitinib. Withdrawal
because of AEs during first-line treatment was significantly
more frequent in the Su-So arm (n = 52, 30%) than in the
So-Su arm (n = 33, 19%; p = 0.02). Cardiac safety parameters
(LVEF and NT-proBNP) were similar between the groups at all
three assessment visits (Supplementary Table 5).
3.4. Post hoc subgroup analyses
Median total PFS and median first-line PFS were generally
similar between the treatment arms across patient sub-
groups categorised according to age, sex, ECOG PS, and
MSKCC score. Differences in median OS reached statistical
significance in subgroups split according to age, with
greater benefits observed for So-Su in patients aged >65 yr
(HR 0.60, 95% CI 0.37–0.97) and for Su-So in patients aged
65 yr (HR 1.57, 95% CI 1.01–2.44). No other significant
differences in OSwere observed between subgroups (Fig. 4).
In the updated OS analysis (cutoff January 14, 2014), the
only significant difference between post hoc subgroups was
that patients aged>65 yr experienced a greater benefit with
So-Su than Su-So (median OS 31.5 vs 19.8 mo; p = 0.04;
Supplementary Table 6) [19]. To explore possible reasons
for the apparent improved OS in older patients who
received So-Su compared with Su-So, the number of
patients aged 65 or >65 yr who received each treatment
line, the duration of treatment for each line, and the
incidence of grade 3/4 AEs were determined (Supplemen-
tary Table 7). In patients aged >65 yr, the mean duration of
first-line treatment was similar in each treatment arm
(35.7 wk So-Su vs 39.8 wk Su-So, p = 0.6); the mean
duration of second-line treatment was 36.0 wk with So-Su
and 12.9 wk with Su-So (p < 0.0001). Rates of grade 3/4 AEs
tended to be higher with sunitinib than with sorafenib in
both the first and second lines of treatment (first line, Su-So
67% vs So-Su 55%, p = 0.1; second line, So-Su 55% vs Su-So
26%, p = 0.02).
4. Discussion
Initiated in 2008, SWITCH was the first prospective,
randomised phase 3 study of sequential tyrosine kinase
inhibitor (TKI) therapy (So-Su vs Su-So) for advanced/
metastatic RCC. Both drugs provided [4_TD$DIFF] overall clinical
benefit, regardless of treatment sequence. The primary
objective was not met: total PFS was not superior with
So-Su versus Su-So (median 12.5 vs 14.9 mo; HR 1.01). OS
was similar in both arms: median 31.5 and 30.2 months
with So-Su and Su-So, respectively (HR 1.00). Likewise, total
TTP was comparable between So-Su and Su-So (15.2 and
17.2 mo; HR 1.01). In both arms, total TTP was approxi-
mately 2.5 mo longer than total PFS. This may have
Table 1 – Patient demographics and baseline characteristics
(intention-to-treat population)
Variable So-Su
(n = 182)
Su-So
(n = 183)
Total
(n = 365)
Median age, yr (range) 64 (39–84) 65 (40–83) 65 (39–84)
Sex, n (%)
Female 43 (24) 48 (26) 91 (25)
Male 139 (76) 135 (74) 274 (75)
Clear cell histology, n (%) 164 (90) 154 (84) 318 (87)
Nephrectomy
(total or partial), n (%)
167 (92) 168 (92) 335 (92)
MSKCC risk score a, n (%)
High 1 (0.5) 1 (0.5) 2 (0.5)
Intermediate 108 (59) 94 (51) 202 (55)
Favourable 71 (39) 82 (45) 153 (42)
Unknown 2 (1.1) 4 (2.2) 6 (1.6)
Missing 0 (0) 2 (1.1) 2 (0.5)
ECOG PS, b n (%)
0 116 (66) 106 (60) 222 (63)
1 55 (31) 66 (38) 121 (34)
2 0 (0) 1 (0.6) 1 (0.3)
Missing 6 (3.4) 3 (1.7) 9 (2.5)
Metastatic sites, b n (%)
Lung 139 (79) 126 (72) [10_TD$DIFF]265 (75)
Lymph nodes 85 (48) 71 (40) 156 (44)
Liver 36 (20) 42 (24) 78 (22)
Bone 22 (12) 30 (17) 52 (15)
Brain 6 (3.4) 4 (2.3) 10 (2.8)
Number of metastatic sites, b n (%)
1 38 (21) 51 (29) 89 (25)
2 68 (38) 59 (34) 127 (36)
3 51 (29) 36 (20) 87 (25)
4 19 (11) 28 (16) 47 (13)
Previous cancer therapies, c n (%)
Interferon-a 2 (1.1) 5 (2.7) 7 (1.9)
Interleukin-2 1 (0.5) 3 (1.6) 4 (1.1)
Other 13 (7.1) 13 (7.1) 26 (7.1)
Radiotherapy 16 (8.8) 23 (13) 39 (11)
Total 26 (14) 31 (17) 57 (16)
ECOG PS = Eastern Cooperative Oncology Group performance status;
MSKCC = Memorial Sloan Kettering Cancer Center; So = sorafenib;
Su = sunitinib.
a Based on central assessment post-randomisation. Imbalance in MSKCC
risk score distribution occurred because of incorrect site entries at
randomisation.
b Presented for the safety population, So-Su n = 177, Su-So n = 176, total
n = 353.
c Some patients received more than one previous cancer treatment. For
two of the patients assigned to the Su-So group, the informationwasmissing.
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methodological reasons as, unlike PFS, calculation of TTP did
not include deaths. Further prospective randomised studies
investigating the optimal sequencing of targeted agents are
ongoing, e.g. the SWITCH-II study (NCT01613846) assessing
sorafenib and pazopanib in sequence [20].
First-line PFS for each agent in SWITCH (sorafenib
5.9 mo; sunitinib 8.5 mo) was within the previously
reported range (4.4–11.6 mo for sorafenib and 5.1–13.1
mo for sunitinib) [10,15,16,21–23]. Second-line PFS with
sorafenib following first-line sunitinib in the phase
3 INTORSECT andAXIS studies (3.9 and 3.4mo, respectively)
[8,11] was also consistent with that seen in SWITCH
(2.8 mo). Both first- and second-line PFS in SWITCH [24_TD$DIFF]were
consistent with results from the largest retrospective study
reported to date (n = 2106 across multiple centres) [24]. In
that study, Alimohamed et al reported first-line PFS of
7.3 mo for sorafenib (n = 412) and 7.2 mo for sunitinib
(n = 1542), and second-line PFS of 3.6 mo for sorafenib
following sunitinib (n = 257), and 5.2 mo for sunitinib
following sorafenib (n = 152) [24]. In SWITCH, second-line
PFS for sunitinib following sorafenib was 5.4 mo. In their
large retrospective study, Alimohamed et al concluded that
the sequence [25_TD$DIFF]in which targeted therapies [26_TD$DIFF] are used does not
substantially affect clinical outcome [24]. While our PFS
findings confirm this observation, response rates appeared
to differ for the treatment sequences. ORR (31% and 29%)
and DCR (69% and 64%) were similar for first-line sorafenib
and sunitinib, respectively. However, compared [27_TD$DIFF]with patients
receiving Su-So, those receiving So-Su had greater second-line
ORR (17% vs 6.6%) and DCR (49% vs 32%). The clinical
relevance of these observations remains unclear, particu-
larly in the context of our PFS findings.
To the best of our knowledge, no other phase 3 studies of
sequential TKI therapy in RCC have been reported. Findings
[28_TD$DIFF]of a phase 2 study [29_TD$DIFF] (RECORD-3) investigating sequential
everolimus followed by sunitinib (Ev-Su) compared with
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Fig. 3 – Kaplan-Meier plots of (A) first-line progression-free survival and (B) second-line progression-free survival (intention-to-treat population).
CI = confidence interval; HR = hazard ratio; PFS = progression-free survival; So = sorafenib; Su = sunitinib.
[(Fig._2)TD$FIG]
Median (90% CI) PFS,
n  mo  mo
So-Su 182 12.5 (11.5–15.0)
Su-So 183 14.9 (10.5–17.2)
HR 1.01 (90% CI 0.81–1.27)
p value for superiority = 0.5
50 10 15 20 25 30 35 40 45 50
182 126 93 66 45 30 17 14 67
183 116 85 62 43 26 19 16 10 9
Time from randomisation (mo)
No. patients
So-Su
Su-So
P
FS
 p
ro
ba
bi
lit
y 
(%
)
0
80
100
40
60
20
Median (90% CI) OS,
n 
So-Su 182 31.5 (23.3–36.9)
Su-So 183 30.2 (23.6–50.1)
HR 1.00 (90% CI 0.77–1.30)
p value for superiority = 0.5
50 10 15 20 25 30 35 40 45 50
6
7
55
182 148 123 105 79 58 36 25 17 9
183 147 119 95 80 59 37 29 18 12
Time from randomisation (mo)
No. patients
So-Su
Su-So
S
ur
vi
va
l p
ro
ba
bi
lit
y 
(%
)
0
80
100BA
40
60
20
Fig. 2 – Kaplan-Meier plots of (A) total progression-free survival and (B) overall survival (intention-to-treat population).
CI = confidence interval; HR = hazard ratio; PFS = progression-free survival; OS = overall survival; So = sorafenib; Su = sunitinib.
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sunitinib followed by everolimus (Su-Ev) were recently
published [25]. Median total PFS was 21.1 mo for Ev-Su
and 25.8 mo for Su-Ev (HR 1.3, 95% CI 0.9–1.7) and OS
was 22.4 mo for Ev-Su and 32.0 mo for Su-Ev (HR 1.2,
95% CI 0.9–1.6). Notably, 207 patients (44%) overall in
RECORD-3 received per-protocol second-line treatment,
similar to the proportion of patients who received second-
line treatment in our study (179 patients, 49%).
One key challenge in managing mRCC is that only
approximately half of patients proceed from first-line to
second-line treatment. In the present study, more patients
reached second-line therapy on protocol in the So-Su
compared with the Su-So arm (57% vs 42%; p < 0.01). This is
consistent with data from other studies suggesting that
patients receiving sorafenib early in the treatment sequence
are more likely to receive subsequent therapies than those
receiving first-line sunitinib (34–38% for sorafenib vs 16–
18% for sunitinib) [26,27]. The reasons for this difference are
not clear. Notably, patients in our study who did not
progress to second-line therapy happened to have more
advanced disease (less favourable MSKCC score and ECOG
PS; more prior treatment) or poorer prognosis (fewer
patients [30_TD$DIFF]had [31_TD$DIFF]undergone nephrectomy; more with non–
clear-cell histologies) than those who did progress to
second-line therapy. Furthermore, differences in the first-
line AE profiles may impact patients’ willingness or ability
Table 2 – Best overall tumour response and disease control rate (modified intention-to-treat population) a
Tumour response [11_TD$DIFF], n (%) First-line therapy Second-line therapy
So-Su
(n = 177)
Su-So
(n = 176)
p value So-Su
(n = 103)
Su-So
(n = 76)
p value
Complete response 5 (2.8) 6 (3.4) 1 (1.0) 1 (1.3)
Partial response 50 (28) 45 (26) 17 (17) 4 (5.3)
Stable disease 68 (38) 61 (35) 32 (31) 19 (25)
Objective response rate b 55 (31) 51 (29) 18 (17) 5 (6.6)
Disease control rate c 123 (69) 112 (64) 0.7 50 (49) 24 (32) 0.03
So = sorafenib; Su = sunitinib.
a Included only patients who received at least one dose of study drug in the respective treatment line. Response evaluation was based on investigator assessment.
b Objective response rate = complete response + partial response.
c Disease control rate = complete response + partial response + stable disease[12_TD$DIFF] 8 wk.
Table 3 – Safety overview
So-Su Su-So
First-line So (n = 177) Second-line Su (n = 103) First-line Su (n = 176) Second-line So (n = 76)
Mean therapy duration, wk (SD) 37.5 (37.4) a,b 28.2 (29.6) c 43.9 (44.3) b 16.0 (15.2) c,d
Dose reductions, n (%) 65 (37) 24 (23) 65 (37) 35 (46)
Dose interruptions, n (%) 81 (46) 30 (29) 71 (40) 26 (34)
Any TEAE, n (%) 172 (97) 90 (87) 172 (98) 64 (84)
Grade 3/4 TEAE, n (%) 117 (66) 53 (51) 118 (67) 27 (36)
AEs leading to withdrawal, n (%) 33 (19) e 20 (19) 52 (30) e 15 (20)
Any serious AE, n (%) 88 (50) 43 (42) 81 (46) 19 (25)
AEs related to deaths, n (%) 12 ( [13_TD$DIFF]6.7) 1 (1.0) 16 (9.1) 2 (2.6)
Most frequent TEAEs f, n (%) All Grade 3/4 All Grade 3/4 All Grade 3/4 All Grade 3/4
Diarrhoea 96 (54) 9 (5.1) 16 (16) 2 (1.9) 70 (40) 5 (2.8) 26 (34) 3 (3.9)
Hand-foot skin reaction 69 (39) 21 (12) 14 (14) 5 (4.9) 38 (22) 10 (5.7) 16 (21) 5 (6.6)
Hypertension 57 (32) 16 (9.0) 11 (11) 3 (2.9) 58 (33) 21 (12) 6 (7.9) 2 (2.6)
Fatigue 56 (32) 8 (4.5) 24 (23) 3 (2.9) 70 (40) 13 (7.4) 9 (12) 0
Alopecia 55 (31) [14_TD$DIFF]– 2 (1.9) [14_TD$DIFF]– 10 (5.7) [14_TD$DIFF]– 4 (5.3) [14_TD$DIFF]–
Rash 48 (27) 3 (1.7) 8 (7.8) 0 10 (5.7) 0 12 (16) 1 (1.3)
Nausea 39 (22) 2 (1.1) 17 (17) 1 (1.0) 53 (30) 3 (1.7) 6 (7.9) 1 (1.3)
Loss of appetite 37 (21) 2 (1.1) 16 (16) 2 (1.9) 30 (17) 4 (2.3) 12 (16) 0
Pain 33 (19) 6 (3.4) 11 (11) 4 (3.9) 25 (14) 4 (2.3) 4 (5.3) 0
Stomatitis 15 (8.5) 0 9 (8.7) 0 37 (21) 8 (4.5) 5 (6.6) 0
Thrombocytopenia 2 (1.1) 1 (0.6) 1 (1.0) 0 11 (6.3) 9 (5.1) 0 0
[1_TD$DIFF]SD = standard deviation; So = sorafenib; Su = sunitinib[15_TD$DIFF]; TEAE = treatment-emergent adverse event.
a n = 176.
b p = 0.1.
c p < [16_TD$DIFF]0.001.
d n = 74.
e p = 0.02.
f Any-grade AE in >20% of patients in either arm, or grade 3/4 AEs in >3% of patients in either arm.
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to continue to second-line treatment, as has been shown
elsewhere [28,29]. The most common reasons cited by
investigators for not continuing to second-line treatment in
SWITCH in the So-Su versus Su-So arms, respectively, were
death (16% vs 19%), AEs (8% versus 17%), and withdrawn
consent (9% vs 13%).
Safety profiles differed between sorafenib and sunitinib,
but were generally as expected and consistent with
previous reports for these agents in patients with mRCC
[30,31]. AEswere generally less frequent during second-line
than first-line therapy. Although the precise reasons are not
known, this observation is consistent with previous data
showing that AEs tend to occur early in the course of TKI
therapy [32,33], and suggests possible cross-tolerance and
adaptation to TKI treatment. Prospective assessment of
cardiac safety (LVEF andNT-proBNP values) was included in
the protocol following previous reports of cardiotoxicity
and reduced LVEF, particularly with sunitinib [30,34–
38]. For example, a meta-analysis found a higher risk of
all-grade and high-grade congestive heart failure, mainly
defined as declines in LVEF, in sunitinib-treated compared
[27_TD$DIFF]with placebo-treated renal and nonrenal cancer patients
[38]. In addition to monitoring andmanaging hypertension,
which may be associated with cardiac events in patients
receiving TKIs [35,37], NT-proBNP represents a more
convenient and potentially more reliable early marker of
cardiac damage than LVEF [39,40]. Results for LVEF and
NT-proBNP monitoring in SWITCH indicated that neither
sorafenib nor sunitinib significantly affected cardiac safety.
This is consistent with findings from an ongoing phase 3,
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randomised, placebo-controlled study of adjuvant sorafenib
or sunitinib in patients with resected, nonmetastatic RCC at
high risk of recurrence (NCT00326898). In that study, LVEF
declines were negligible, occurring in only 2.3%, 1.8%, and
1.0% of patients receiving sunitinib, sorafenib, and placebo,
respectively [41].
Subgroup analyses for age, sex, risk of recurrence, and
baseline performance status (ECOG PS 0 vs 1) revealed
no differences between So-Su and Su-So in terms of total
PFS, OS, or first-line PFS apart from[32_TD$DIFF] statistically significant
differences in OS according to age, with the results favouring
So-Su in patients aged >65 yr (Fig. 4B and Supplementary
Table 6) [19]. The reasons for this difference are unclear.
The study design did not include patient stratification
according to age, and our observations should be considered
as hypothesis-generating only. Nonetheless, it is interesting
that sorafenib appeared to be somewhat better tolerated
than sunitinib in elderly patients in our study[33_TD$DIFF]. [34_TD$DIFF] ndeed, age
was included in our subgroup analyses as previous analyses
suggested that sorafenib is effective and well tolerated[5_TD$DIFF]
particularly in elderly patients [33,42–44].
The study has a number of limitations to be considered
when interpreting the results. The study was open-label
rather than double-blind, introducing a potential for investi-
gator bias; however, the protocol mandated that confirmed
radiologic progression was required to stop treatment on
the grounds of disease progression, which reduced this
potential for bias. The findings for second-line PFS may not
be robust because there were low numbers of patients/
events; fewer patients received on-study second-line treat-
ment with sunitinib compared with sorafenib; and only
selected subsets of patients were able to receive second-
line treatment. The results for second-line therapy should
therefore be interpreted with caution. OS could have
been confounded by subsequent treatments received after
patients completed per-protocol therapy. Limited prospec-
tive sequential data were available at the time at which the
study was designed, so it was not possible to estimate the
impact that an imbalance in discontinuation could have on
the study findings, particularly in terms of total PFS and
second-line PFS. The different safety profiles of sorafenib and
sunitinib may have contributed to differences in first-line
therapy discontinuation, and thus affected first-line PFS and
total PFS. In sequential studies, the decision to end first-line
treatment can potentially be influenced by investigator
knowledge that a second-line treatment is readily available.
In SWITCH, however, confirmed radiologic progression was
required to proceed to second-line treatment.
5. Conclusions
SWITCH is the first prospective, randomised, phase 3 study
of sequential TKI therapy (So-Su vs Su-So) for advanced/
metastatic RCC; 49% of patients received per-protocol
second-line therapy. The primary endpoint of total PFS
was not met, but the results did confirm the clinical benefit
of sequential treatment, with median OS of approximately
30 mo. Further prospective randomised studies investigat-
ing the optimal sequencing of targeted agents are ongoing.
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